Last reviewed · How we verify
NCT03272529: PCNL
Simulated Rehearsal for Percutaneous Nephrolithotomy
trial testing Patient-specific simulated rehearsals in Nephrolithotomy in 36 participants. Completed in 31 January 2023.
31 January 2023
Quick facts
| Lead sponsor | University of Rochester |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 36 |
| Start date | 10 April 2018 |
| Primary completion | 31 January 2023 |
| Estimated completion | 31 January 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Patient-specific simulated rehearsals
- Idealized simulated rehearsals
- Standard simulation
Conditions studied
- Nephrolithotomy — all drugs for Nephrolithotomy →
Sponsor
University of Rochester
Who can join
18 and older, any sex, with Nephrolithotomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Surgical simulation provides opportunities for surgeons to practice specific skills, prior to performing complex tasks on patients, with the goal of reducing potential errors and providing a safer procedure for the patient. The investigators will use a novel approach to simulation (patient-specific rehearsals) i.e., practice a short time prior to the live event that uses gel models of organs created by a 3D printer, and that are specific to each patient versus models that represent an ideal training model. The investigators' overarching goals are to improve patient outcomes by developing the best platform for surgeons to efficiently enhance performance prior to live surgery.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
From ideas to long-term studies: 3D printing clinical trials review.
Witowski J, Sitkowski M, Zuzak T, Coles-Black J, et al · · 2018 · cited 39× · PMID 29790077 · DOI 10.1007/s11548-018-1793-8 -
Current Biomedical Applications of 3D-Printed Hydrogels.
Barcena AJR, Dhal K, Patel P, Ravi P, et al · · 2023 · cited 17× · PMID 38275845 · DOI 10.3390/gels10010008 -
Next-generation epidermal patches: Bridging 3D and multidimensional printing for biomedical and personal care innovations.
El-Khordagui LK, El-Habashy SE, Simchi A, Tohamy HS, et al · · 2026 · PMID 42005999 · DOI 10.1016/j.bioactmat.2026.03.054
Verify or expand the search:
- PubMed search for NCT03272529
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Rochester trials
Trials by the same sponsor.
- NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
- NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
- NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03272529 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Rochester
- Last refreshed: 10 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03272529.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing